Pair Name	Rhizoma Paridis saponins, Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Glycolysis
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
	Down-regulation	Expression	CPT1A	hsa1374
	Down-regulation	Expression	CPT1A	hsa1374
	Up-regulation	Activity	DUOX2	hsa50506
	Down-regulation	Expression	FASN	hsa2194
	Down-regulation	Expression	HIF1A	hsa3091
	Down-regulation	Expression	LDHA	hsa3939
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Down-regulation	Expression	MYC	hsa4609
	Down-regulation	Phosphorylation	PIK3CA	hsa5290
	Up-regulation	Activity	SDHB	hsa6390
	Down-regulation	Expression	SLC2A1	hsa6513
	Up-regulation	Expression	TP53	hsa7157
In Vivo Model	5×10⁶ of H22 tumor cells were subcutaneously subaxillary inoculated in 24 mice.
Result	All of that provided possibility to overcome the intolerance of sorafenib by drug compatibility through protection against mitochondria damage, inhibition of anaerobic glycolysis and suppression of lipid synthesis based on PI3K/Akt/mTOR pathway.